Natco Pharma Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q651ip5edom1p3zb06llf4f4.pdf

Key Takeaways


FY26 Guidance: The Downward Reset

Rajeev Nannapaneni: "I think people are harsh when you say something higher and then we deliver, then market is harsh. So, it's better to say something less then deliver more. So, I think that's what I've learned."

Pipeline Catalysts: Binary Outcomes, Distant Timelines

Rajeev Nannapaneni: "Moonshots make money, don't discount moonshots. A lot of our moonshots have been successful."

Revlimid: The Managed Decline


India Business: Base Growth Plus Launch Optionality


Crop Health & Other Segments: The Turnaround Bet


Strategic Bets: NCEs, Cell & Gene Therapy, and Inorganic Moves

Rajeev Nannapaneni: "I think you have to reimagine your business every few years, right? So, I mean, a pure generics play is going to be very competitive and your moonshot ideas cannot stick only to generics, right? You need to also look at NCE."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue and profitPossible dip in revenue by 20% and profits by 30%FY26 full year
FY26 R&D spendTargeting up to INR400 croresFY26
India base business growth7% to 10% growthFY26
Risdiplam launchLaunch immediately if court order is favorableOrder expected June 2025
Semaglutide launchExpected maybe end of the financial yearFY26
Crop Health breakevenHit INR160-170 crores revenue to be EBITDA positiveThis year (FY26)
NRC-2694 trial enrollmentRecruit 60-70 patientsNext 1-1.5 years
NCE molecule clarityClarity on where the trial is goingNext 12-18 months
Inorganic deal closureClose a deal, possibly a U.S. manufacturing or distribution baseThis financial year (FY26)
U.S. filings7 to 8 filings targetedFY26

Key Metrics

MetricQ4 FY25
Consolidated revenue₹1,287.3 cr, vs ₹1,110.3 cr in Q4 FY24
Consolidated net profit₹406 cr, vs ₹386.3 cr in Q4 FY24
Full-year FY25 consolidated revenue₹4,784 cr, +16% YoY
Full-year FY25 consolidated net profit₹1,883.4 cr, +36% YoY
FY26 revenue guidance~20% dip expected, due to geopolitical uncertainties
FY26 PAT guidance~30% dip expected
R&D spend (FY25)₹373 cr, 8.5% of stand-alone revenue
R&D spend (FY26 target)Up to ₹400 cr
Cash positionOver ₹3,500 cr
Impairment charge (Crop Health Science)₹50 cr, related to property, plant and machinery
Chargeback adjustment (U.S. subsidiary)~₹25 cr
India base business growth expectation (FY26)7% to 10%
Crop Health Science net revenue (FY25)~₹60 cr
Crop Health Science segment loss (FY25)~₹150 cr, including impairment
Non-U.S. formulation exports (FY25, estimate)~₹800 cr to ₹900 cr
Annual capex run-rate~₹300 cr to ₹350 cr